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Flavin-containing  monooxygenases  (FMOs)  catalyse  asymmetric  oxidation  reactions  that  have  poten-
tial  for  preparative  organic  synthesis,  but most  use the  more  expensive,  phosphorylated  nicotinamide
cofactor  NADPH  to  reduce  FAD  to FADH2 prior  to formation  of  the  (hydro)peroxy  intermediate  required
for substrate  oxygenation.  A comparison  of  the  structures  of  NADPH-dependent  FMO  from  Methylophaga
aminisulﬁdivorans  (mFMO)  and  SMFMO  from  Stenotrophomonas  maltophilia,  which  is able  to  use  both
NADPH  and  NADH,  suggested  that the  promiscuity  of the  latter  enzyme  may  be  due  in  part  to the
substitution  of  an Arg–Thr  couple  in  the  NADPH  phosphate  recognition  site  in  mFMO,  for  a  Gln–His
couple  in SMFMO  (Jensen  et  al., 2012,  Chembiochem, 13, 872–878).  Natural  variation  within  the phos-
phate  binding  region,  and  its inﬂuence  on nicotinamide  cofactor  promiscuity,  was explored  through  the
cloning,  expression,  characterisation  and  structural  studies  of FMOs  from  Cellvibrio  sp.  BR  (CFMO)  and
Pseudomonas  stutzeri  NF13  (PSFMO),  which  possess  Thr–Ser  and Gln–Glu  in  the  putative  phosphate  recog-
nition  positions,  respectively.  CFMO  and PSFMO  displayed  5- and  1.5-fold  greater  activity,  respectively,
than  SMFMO  for the  reduction  of  FAD  with  NADH,  and  were  also  cofactor  promiscuous,  displaying  a
ratio  of activity  with  NADH:NADPH  of 1.7:1  and  1:1.3,  respectively.  The  structures  of  CFMO  and  PSFMO
revealed  the  context  of  the phosphate  binding  loop  in each  case,  and  also  clariﬁed  the  structure  of  the
mobile  helix–loop–helix  motif  that  appears  to shield  the  FAD-binding  pocket  from  bulk solvent  in this
class  of  FMOs,  a feature  that was absent  from  the  structure  of  SMFMO.
© 2014  The  Authors.  Published  by  Elsevier  B.V.  This  is  an  open  access  article  under the  CC  BY-NC-ND. Introduction
Flavin-containing monooxygenases (FMOs) [1] catalyse the
xygenation of heteroatoms, such as nitrogen and sulfur, in various
rganic substrates, and have been studied both for their role in
etabolism in higher eukaryotes, including humans [2,3], and
lso for their contributions to microbial metabolism, in which
hey are able to catalyse the oxidation of amines [4] and amino
cids such as ornithine [5]. In the case of microbial enzymes, the
dentiﬁcation of interesting FMO  activity has led to the exploitation
f those enzymes for biotechnological applications [6,7], in which
he enzymatic characteristics of high turnover rates and chemo-,
egio- and enantioselectivity, are very valuable. FMOs typically
∗ Corresponding author. Tel.: +44 1904 328266; fax: +44 1904 328266.
E-mail address: gideon.grogan@york.ac.uk (G. Grogan).
ttp://dx.doi.org/10.1016/j.molcatb.2014.08.019
381-1177/© 2014 The Authors. Published by Elsevier B.V. This is an open access article unlicense (http://creativecommons.org/licenses/by-nc-nd/3.0/).
employ the phosphorylated nicotinamide cofactor NADPH to
reduce a molecule of FAD within the enzyme, which then reacts
with molecular oxygen to form a (hydro)peroxy ﬂavin species that
is the catalytic oxidant in reaction [1]. A well-studied example
of a bacterial FMO  is that from Methylophaga aminisulﬁdivorans
(Uniprot Q83XK4, mFMO), an enzyme of monomer molecular
weight 46 kDa that was  identiﬁed on the basis of its ability to
form the pigment indigo through oxidative transformation of
indole [8]. mFMO  has also been shown to catalyse the asymmetric
sulfoxidation of a series of prochiral thioethers, when employed
as part of a fusion enzyme with phosphite dehydrogenase for
the recycling of the nicotinamide cofactor [9]. Studies of mFMO
have shown a dependence for the phosphorylated cofactor
NADPH, but the lower cost of the non-phosphorylated analogue,
NADH, has meant that recent studies of FMOs have been directed
towards enzymes that might employ that cofactor for ﬂavin
reduction.
der the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
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We  recently reported the cloning, expression and structural
haracterisation of another FMO, named SMFMO, from the marine
acterium Stenotrophomonas maltophilia [10]. This target was inter-
sting as it displayed the ability to use either NADPH or NADH as
he cofactor for reduction of the ﬂavin. SMFMO  was hence able
o use NADH, along with a formate dehydrogenase/sodium for-
ate based recycling system, to catalyse the asymmetric oxidation
f thioethers, and also the Baeyer–Villiger oxidation of a strained,
used cyclobutanone substrate [10]. Related activities have recently
een described by the group of Fraaije, who have characterised
ther FMOs, notably FMO-D, from Rhodococcus jostii RHA1, related
o SMFMO, and which are similarly able to employ NADPH or
ADH [11]. The structure of SMFMO  was determined [10], and
nalysis of the nicotinamide cofactor binding loop revealed dif-
erences between NADPH-dependent mFMO  [12–14] and SMFMO
hat might be signiﬁcant in the recognition of the NADPH 2′ ribose
hosphate that distinguishes NADPH and NADH [10]. In this region
n mFMO,  Arg234 and Thr235 project towards the phosphate and
nteract directly with the phosphate oxygen atoms, whereas in
MFMO  Gln193 and His194 are found in equivalent positions.
 double mutant of SMFMO  that was designed to mimic  the
hosphate binding loop of mFMO,  changed the preference of the
nzyme for NADPH to NADH from a ratio of 1.5:1 to 1:3.5 [15].
hese mutations were not successful in removing activity with
ADH, however. Multiple studies on the wider group of NAD(P)H-
ependent ﬂavoprotein monooxygenases (FPMOs) have shown
hat, whilst positively charged basic residues are often involved in
he speciﬁc recognition of negatively-charged phosphate [16–18],
ADH-dependent activity can be engineered through the mutation
f the cofactor binding loop to include a negatively charged car-
oxylate side chain enzymes that excludes phosphate, presumably
hrough charge repulsion [19]. Engineering a glutamate residue
nto the cofactor-binding loop of SMFMO, in an attempt to gen-
rate a more NADH-speciﬁc variant, resulted in a mutant that was
ot produced in the soluble fraction of the Escherichia coli strain
sed for gene expression, however [15]. In this report, we describe
he cloning, expression, and characterisation of two homologs of
MFMO, CFMO from Cellvibrio sp. BR (Uniprot code I3IEE4) and
SFMO from Pseudomonas stutzeri NF13 (M2V3J0). These homologs
isplay natural variation in the cofactor-binding loop, Thr–Ser in
FMO and Gln–Glu in PSFMO, which suggested there may  be altered
ofactor preference compared to either mFMO  or SMFMO. The
nzyme activity with NADH and NADPH and a range of prochi-
al sulﬁdes is assessed, and the structures of the enzymes, which
eveal the context of the substituted amino acids within the puta-
ive cofactor binding loop, are presented.
. Experimental
.1. Chemicals
Chemicals, including media and buffer components, sulﬁde sub-
trates and cofactors were purchased from Sigma-Aldrich (Poole
.K.).
.2. Gene synthesis, cloning, expression and protein puriﬁcation
The genes encoding CFMO and PSFMO were synthesised
y GeneArt (Invitrogen), with sequences optimised for expres-
ion in E. coli using the GeneArt server program. Genes were
hen ampliﬁed by PCR from the commercial genes using the
ollowing primers: For CFMO: Forward: CCAGGGACCAGCAATG-
ATACACCGGTTATGG; Reverse: GAGGAGAAGGCGCGTTAGGCGC-
ATCCAGATACTG; For PSFMO: Forward: CCAGGGACCAGCAATGC-
TCCGATTCTGG; Reverse: GAGGAGAAGGCGCGTTACGGACGACG-
CTCGG. PCRs were analysed on agarose gels, and bands of thesis B: Enzymatic 109 (2014) 191–198
expected size were isolated using a PCR Cleanup kit® (Qiagen). Tar-
get genes were then sub-cloned into the pET-YSBL-LIC-3C vector
following a previously published procedure [20]. The recombinant
plasmids were then used to transform cells of E. coli XL1-Blue
(Novagen), which, after transformation and overnight growth on LB
agar containing 30 g mL−1 kanamycin as antibiotic marker, were
subjected to miniprep procedures that resulted in plasmids suit-
able for DNA sequencing. Once the sequence of the genes had been
conﬁrmed, gene expression was conducted by transforming cells
of E. coli BL21 (DE3) with the recombinant plasmids. 5 mL  of LB
medium containing 30 g mL−1 kanamycin was  inoculated with a
single colony of the relevant strain. This starter culture was  grown
at 37 ◦C overnight with shaking at 180 r.p.m. Each 5 mL  culture was
then used to incolulate 500 mL  LB broth containing 30 g mL−1
kanamycin in a 2 L Erlenmeyer ﬂask. These larger cultures were
grown with shaking at 37 ◦C until the optical density, as deter-
mined by measurement at 600 nm, had reached 0.8. The cultures
were then induced through the addition of 1 mM isopropyl -
D-1-thiogalactopyranoside (IPTG), and growth continued at 18 ◦C
overnight. Cells were then harvested by centrifugation for 15 min
at 4225 g using a Sorvall GS3 rotor in a Sorvall RC5B Plus centrifuge.
Following centrifugation, the resultant cell pellets were resus-
pended in 25 mL  50 mM  Tris/HCl buffer pH 7.5, containing 300 mM
sodium chloride (‘buffer’) per L of cell growth. These suspensions
were then subjected to cell disruption using an ultrasonicator for
3 × 30 s periods at 4 ◦C with intervals of 1 min. The soluble fraction
after sonication was recovered by centrifuging the suspension for
30 min  at 26,892 g in a Sorvall SS34 rotor. Supernatants were then
ﬁltered using a 2 m Amicon ﬁlter, and then subjected t nickel afﬁn-
ity chromatography using a 5 mL  His-TrapTM Chelating HP column.
After loading the ﬁltered protein solution, the column was washed
with ﬁve column volumes of buffer containing imidazole (30 mM).
The FMOs were then eluted from the column using a 30–500 mM
imidazole gradient over twenty column volumes. Column fractions
containing FMOs were identiﬁed using SDS-PAGE and combined.
Pooled fractions were concentrated, typically, to a volume of 4 mL
using a Centricon® ﬁlter membrane (10 kDa cut-off) and 2 mL of
this solution then loaded onto an S75 SuperdexTM 16/60 size exclu-
sion column that had been pre-equilibrated with buffer. FMOs were
eluted with buffer at a ﬂow rate of 1 mL  min−1. Fractions were ana-
lysed by SDS-PAGE and those that contained pure FMOs  pooled and
stored at 4 ◦C for crystallisation, enzyme assays or biotransforma-
tions. For the purposes of crystallisation, the histidine tags of CFMO
or PSFMO were cleaved using 3 C protease and using a procedure
described previously [20]. Typical CFMO and PSFMO preparations
yielded 20 mg  and 7.5 mg  pure protein per litre of cells, respectively.
2.3. Enzyme assays
Steady-state kinetic constants for the NADH and NADPH-
dependent reduction of FAD by the FMOs were determined
using the method employed previously [10,21]. In a 1 mL  quartz
cuvette containing Tris–HCl buffer pH 7.5 (50 mol) the decrease
in absorbance at 340 nm was  monitored for concentrations of
NAD(P)H (10–100 M)  after the addition of enzyme (CFMO or
PSFMO, 3.9 nmol). All data points represented the average of three
separate runs. Kinetic constants (KM and kcat) were calculated using
a value for ε of 6220 mol  dm−3 cm−1 using GraﬁtTM (Erithacus
Sofware).
2.4. BiotransformationsBiotransformations using isolated enzymes with cofactor
recycling were performed using the method previously described
for SMFMO  [10]. For NADH-dependent biotransformations: To
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Table  1
Data collection and resolution statistics for CFMO and PSFMO. Values for the highest resolution shells are given in parentheses.
CFMO PSFMO
Beamline Diamond i24 Diamond i24
Wavelength (Å) 0.96862 0.96862
Resolution (Å) 22.44–2.39 (2.45–2.39) 35.94–1.83 (1.88–1.83)
Space  group C2 P3221
Unit  cell a = 115.41; b = 95.09; c = 92.37 a = b = 63.56; c = 189.82
˛  =  ˇ = 90.0;  = 126.3  ˛ =  ˇ = 90.0;  = 120.0
No.  of molecules in the asymmetric unit 2 1
Unique reﬂections 31344 (2329) 41893 (3176)
Completeness (%) 98.1 (98.4) 100 (99.9)
Rmerge (%) 0.09 (0.50) 0.112 (0.62)
Rp. i. m. 0.09 (0.50) 0.054 (0.30)
Multiplicity 3.2 (2.9) 9.8 (9.9)
〈I/(I)〉 9.0 (2.1) 14.9 (3.8)
CC1/2 0.99 (0.76) 1.00 (0.90)
Overall B factor from Wilson plot (Å2) 25 13
Rcryst/Rfree (%) 24.6/28.7 16.2/20.4
r.m.s.d. 1–2 bonds (Å) 0.014 0.02
r.m.s.d. 1–3 bonds (◦) 1.66 2.26
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 10 mL  round bottomed ﬂask containing Tris–HCl buffer pH
.5 (5 mL)  were added substrate(s) (1–6 in 100 L ethanol to
 ﬁnal concentration of 5 mM),  NADH (5 mg,  a ﬁnal concentra-
ion of 0.7 mM),  formate dehydrogenase (5 mg), sodium formate
6.8 mg,  0.1 mmol) and CFMO or PSFMO (1 mL  of a 5 mg  mL−1
olution, 0.13 mol). The reactions were then stirred for 24 h
t room temperature. Aliquots (500 L) were taken at intervals
nd extracted with ethyl acetate (500 L). The organic layer was
ransferred to a GC vial and analysed by GC as described previ-
usly [10]. For NADPH-dependent biotransformations: To a 10 mL
ound bottomed ﬂask containing Tris–HCl buffer pH 7.5 (5 mL)
ere added substrate(s) (1–6 in 100 L ethanol to a ﬁnal con-
entration of 5 mM),  NADPH (5.7 mg,  a ﬁnal concentration of
.7 mM),  glucose-6-phosphate-dehydrogenase (0.14 mg), glucose-
-phosphate (5.2 mg,  0.02 mmol) and CFMO or PSFMO (1 mL  of a
 mg  mL−1 solution, 0.13 mol). The reactions were then stirred
or 24 h at room temperature and organic extracts of 500 L
liquots analysed as previously [10]. Chiral analysis of sulfoxide
roducts was carried out using BGB 173 and BGB-175 columns
30 m × 0.25 mm × 0.25 m;  each from BGB-Analytik) according to
rocedures described previously [10].
.5. Protein crystallisation
Pure PSFMO and CFMO was subjected to crystallisation trials
sing a range of commercially available screens in 96-well plates
mploying 300 nL drops at a range of protein concentrations (3,
0 and 20 mg  mL−1). The best crystals for PSFMO were obtained
sing the Clear Strategy Screen (CSS) [22] conditions containing
5% (w/v) tacsimate pH 7.0 and His6-tag cleaved protein at a con-
entration of 20 mg  mL−1. The best crystals for CFMO were obtained
sing the CSS conditions containing 1.5 M ammonium sulfate and
on-cleaved protein at 20 mg  mL−1. Larger crystals for diffrac-
ion analysis using optimised conditions were prepared using the
anging-drop vapour diffusion method in 24-well plate Linbro
ishes and using crystallisation drops of 2 L, comprised of 1 L of
eservoir solution and 1 L of protein solution at 20 mg  mL−1. For
SFMO, the best crystals were again obtained in crystal drops con-
aining 35% (w/v) tacsimate at pH 7.0 with no further additions. For
FMO, the best crystals were obtained in crystal drops containing
.5 M ammonium sulfate and 1% propan-2-ol (v/v) at pH 7.0. Crys-
als were ﬂash-cooled in a cryogenic solution containing the mother
iquor with 10% (v/v) glycerol, and tested for diffraction using a19
22
24
Rigaku Micromax-007HF generator ﬁtted with Osmic multilayer
optics and a MARRESEARCH MAR345 imaging plate detector. Crys-
tals that diffracted to a resolution of greater than 3 A˚  were retained
for full dataset collection at the synchrotron.
2.6. Data collection, structure solution, model building and
reﬁnement of CFMO and PSFMO
Datasets described herein were collected at the Diamond Light
Source, Didcot, Oxfordshire, U.K. Data for CFMO and PSFMO were
each collected on beamline I24. Data were processed and inte-
grated using XDS [23] and scaled using SCALA [24] included in the
Xia2 processing system [25]. Data collection statistics are given in
Table 1. The crystals of CFMO were in space group C2. The struc-
ture of CFMO was solved using MOLREP [26], using a monomer
model of SMFMO  (PDB code 4a9w) [10]. The solution contained
two molecules in the asymmetric unit, representing one dimer,
and the solvent content was 55%. The crystals of PSFMO were in
space group P3221. The structure of PSFMO was again solved using
SMFMO  as a model, but in this case, the solution contained only one
molecule in the asymmetric unit. The solvent content in this case
was 57%. The structures of CFMO and PSFMO were built and reﬁned
using iterative cycles using Coot [27] and REFMAC [28], employing
local NCS restraints in reﬁnement. The ﬁnal structures exhibited
Rcryst and Rfree values of 24.6 and 28.7 (CFMO)  and 16.2 and 20.4%
(PSFMO), respectively. Each structure was  validated prior to depo-
sition using PROCHECK [29]. Reﬁnement statistics for all structures
are presented in Table 1. The Ramachandran plot for CFMO showed
93.4% of residues to be situated in the most favoured regions, 6.2% in
additional allowed and 0.5% residues in outlier regions. For PSFMO,
the corresponding values were 92.8%, 4.6% and 2.6%, respectively.
The coordinates and structure factors for CFMO and PSFMO have
been deposited in the Protein Data Bank with the accession codes
4usq and 4usr, respectively.
3. Results and discussion
3.1. Target selectionFollowing the failure to incorporate a glutamate residue within
the cofactor binding loop of SMFMO  that might engender discrimi-
natory binding of NADH over NADP in that enzyme, it was decided
to select targets from the genomic databanks representative of
194 C.N. Jensen et al. / Journal of Molecular Catalysis B: Enzymatic 109 (2014) 191–198
F man m
p etatio
v
n
t
I
w
a
c
i
a
m
a
6
a
m
a
t
i
o
r
r
P
f
t
c
s
b
3
t
m
m
m
which were each lower than for SMFMO. kcat/KM was  slightly
lower with NADH (1880 M−1 s−1) than NADPH (2350 M−1 s−1),
indicating a preference for NADPH in this case of 1.3, but
Table 2
Kinetic constants for CFMO and PSFMO in the reduction of ﬂavin by either NADH or
NADPH. Values for SMFMO, reproduced from Ref. [10] are also given for comparison.
Enzyme/cofactor KM (M) kcat (s−1) kcat/KM (M−1 s−1)
SMFMO* 24 ± 9 0.03 1250
NADH
SMFMO  27 ± 5 0.02 740
NADPH
CFMO 3 ± 1 0.02 6670
NADH
CFMO 5 ± 1 0.02 4000
NADPH
PSFMO 16 ± 2 0.03 1880ig. 1. Sequence alignment of SMFMO, CFMO and PSFMO. The characteristic Ross
roposed to be the closest to the 2′ ribose hydroxyl phosphate in red. (For interpr
ersion of this article.)
atural variation within that loop, particularly corresponding to
he Arg–Thr and Gln–His couples of mFMO  of SMFMO, respectively.
t was hoped that these variants might be sufﬁciently different
ithin the loop to display a shift in preference for one nicotin-
mide cofactor, preferably NADH, over NADPH. CFMO (Uniprot
ode I3IEE4) and PSFMO (M2V3J0) were selected on this basis. Each
s a putative FMO  of a similar size to SMFMO  (361 and 358 amino
cids, respectively, versus 357 for SMFMO) and contains two  Ross-
an  domains and the FXGXXXHXXXY FMO  motif [30]. A sequence
lignment of these targets and SMFMO  (Fig. 1) revealed 58% and
1% sequence identity between CFMO and SMFMO and PSFMO
nd SMFMO, respectively. In place of the Arg234Thr235 couple in
FMO  or Gln193His194 couple in SMFMO, CFMO possessed Ser202
nd Thr203, and PSFMO, Gln194 and Glu195, respectively. The lat-
er was particularly interesting in being one of the only homologs
dentiﬁed from database searches as having either a glutamate
r aspartate residue within the putative phosphate recognition
egion. No homolog was identiﬁed yet that possessed a Glu or Asp
esidue in place of Gln193 in SMFMO. Genes encoding CFMO and
SFMO were synthesised, subcloned and expressed in the soluble
ractions of transformed strains of E. coli BL21 (DE3). The pro-
eins were readily puriﬁed using nickel afﬁnity and size exclusion
hromatography as described in Section 2, each yielding protein
olutions of a bright yellow colour, indicative of the presence of
ound FAD.
.2. Cofactor promiscuity in the reduction of FAD
The ability of CFMO and PSFMO to use either NADH or NADPH
o reduce FAD was assessed using standard UV spectrophoto-
etry assays [10,21], in which the oxidation of NAD(P)H was
onitored at 340 nm.  Kinetic parameters (Km and kcat) were deter-
ined for each enzyme and each cofactor and the results areotifs are highlighted in blue; the FMO  motif [30] in green, and the two residues
n of the references to color in this ﬁgure legend, the reader is referred to the web
shown in Table 2, with data for SMFMO  [10] reproduced for
comparison.
The ﬁrst observation was that both CFMO and PSFMO were both
able to accept NADH or NADPH for the reduction of FAD. CFMO was
observed to bind both NADH and NADPH with increased afﬁnity
compared to SMFMO, as illustrated by Km values of 3 and 5 M com-
pared to values in the range of 24–27 M for NADH and NADPH,
respectively. Although kcat values were lower for CFMO than the
other two enzymes, the low Km contributed to CFMO having a cat-
alytic activity, as determined by values of kcat/KM, of 5.3 and 5.4
fold greater than SMFMO  for NADH and NADPH, respectively. These
values also reveal a slight preference for NADH by a factor of 1.7,
compared with SMFMO, for which the value was 1.5. For PSFMO,
the KM was similar with either NADH (16 M)  or NADPH (17 M)NADH
PSFMO 17 ± 2.0 0.04 2350
NADPH
* Data taken from Ref. [10].
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ach value was again higher than that for SMFMO with either
ofactor.
.3. Biotransformations of prochiral sulﬁdes using CFMO and
SFMO using either NADH or NADPH as cofactor
Both CFMO and PSFMO were then challenged with a range of
rochiral sulﬁde substrates 1–6 (Fig. 2), with the addition of either
atalytic NADH or NADPH as cofactor, and in the presence of a
uitable cofactor recycling system, as had been used for SMFMO
10]. The results of all biotransformations by CFMO and PSFMO,
ompared to those obtained with SMFMO  are shown in Table 3.
FMO oxidised sulﬁdes 1 and 3–6 to, for the most part, their corre-
ponding (R)-sulfoxides, with either cofactor. However, substrate
 was transformed to the (S)-sulfoxide in the presence of NADPH.
he conversions were overall higher with NADH, however, the
nantiomeric excess of sulfoxide products was slightly higher with
ADPH in general. Substrate 2 was not converted by CFMO in
he presence of either cofactor. The highest conversion was seen
or substrate 3, methyl tolyl sulﬁde, with 65% for NADH (22% e.e.
R)-sulfoxide product) and 32% for NADPH (32% e.e.). The most
nantioselective transformation was that of substrate 6 with 66%
(R) and 77% -(R) for achieved with NADH or NADPH, respectively.
FMO was overall less active than SMFMO  with sulﬁde substrates
nd NADH, although both the conversion and product enantiomeric
xcess in the oxidation of phenyl methyl sulﬁde 4 were superior.
nterestingly, when NADPH was employed as nicotinamide cofactor
FMO gave higher conversions compared to SMFMO, except for
ubstrate 3, possibly indicative of its greater activity as shown by
he kinetic constants. For PSFMO, the highest conversions were
bserved for substrate 3 and 4, but enantioselectivity was  poor in
ach case. PSFMO again gave (R)-sulfoxide products for the most
art. The most enantioselective reaction was observed for substrate
, yielding (R)-sulfoxide product of 85% and 57% with NADH and
able 3
esults of biotransformations of prochiral sulﬁde substrates 1 and 3–6 by CFMO or PS
eproduced from Ref. [10] are also given for comparison.
Sulﬁde NADH 
Conversion (%); absolute conﬁguration; e.e. 
SMFMO* CFMO PSFMO 
1 27, (R)-, 71% e.e. 17, (R)-, 54% e.e. 61, (R)-, 30% e.e
3  90, (R)-, 25% e.e. 65, (R)-, 22% e.e. 97, (R)-, 47% e.e
4  8, (R)-, 21% e.e. 64, (R)-, 58% e.e. 99, (R)-, 14% e.e
5  6, (S)-, 15% e.e. No conversion 13, (S)-, 10% e.e.
6  40, (R)-, 80% e.e. 14, (R)-, 66% e.e. 50, (R)-, 85% e.e
* Data taken from Ref. [10].
.d. = not determined.sis B: Enzymatic 109 (2014) 191–198 195
NADPH, respectively. Overall, PSFMO catalysed sulfoxidation reac-
tions gave higher conversions than either SMFMO  or CFMO, but
with poorer e.e.s overall, save for substrate 6.
3.4. Structures of CFMO and PSFMO
In order to shed light on the nature of the cofactor binding loops
in CFMO and PSFMO, the structures of each in complex with the
ﬂavin FAD were determined to resolutions of 2.39 A˚ and 1.83 A˚,
respectively. Crystals of CFMO grew in the C2 space group, with
two molecules ‘A’ and ‘B’, representing one dimer in the asymmet-
ric unit. The CFMO dimer was  made up of two monomers (Fig. 3b),
sharing an interfacial area of approximately 1207 A˚2. Analysis of
the CFMO structure using PISA [31] found that the interactions
that stabilise the dimer included six hydrogen bonds, including
those between the backbone nitrogen of Trp108(A) and the side
chain oxygen of Glu124(B) and the side chain N H of Gln320(A)
with the backbone carbonyl of Ile145(B). The calculated dissoca-
tion energy of the dimer interface (iG) was  −4.4 kcal mol−1. The
monomer of CFMO superposed with the structure of the SMFMO
monomer with an r.m.s.d. of 0.77 A˚ over 317 C atoms. The sec-
ondary elements of the structure are summarised in Fig. 3a. Each
CFMO monomer consists of two domains, an FAD binding domain
and the putative substrate binding domain. Electron density was
visible for the majority of the backbone in each monomer, from
residue Ser13 to Ala361, with a stretch of missing density corre-
sponding to six amino acids between positions Gln236 and Asp243
(PVGGLG) in subunit A and ﬁfteen between Ala227 and Asp243
(AQEGREIEQPVGGLG) in subunit B that could not be modelled. Side
chain density in the region of residues 224–236 in subunit A was
also missing. It appears that the residues for which there is poor
electron density are part of a ﬂexible helix–loop–helix structure,
incorporating helix 8, which is found over the FAD binding pocket,
perhaps shielding the active site from bulk solvent. An equiva-
lent region of density was  missing in structures of both wild-type
SMFMO  (4A9W) [10] and the Gln193Arg/His194Thr mutant (4C5O)
[15]. There was substantial residual density in the omit map  in the
putative active site following building and reﬁnement of the pro-
tein atoms of CFMO. This was successfully modelled and reﬁned as
FAD in the ﬂat, oxidised form.
Crystals of PSFMO grew in the P3221 space group, with one
molecule in the asymmetric unit, although both size-exclusion
studies (not shown), and the relationship of the monomer to its
closest crystallographic symmetry partner, are strongly suggestive
of an active dimer for PSFMO as with SMFMO and CFMO. Anal-
ysis of a dimer pair by PISA [31] revealed an interfacial area of
955 A˚2, with six H-bonds and 8 salt bridges formed between the
monomers. The calculated dissociation energy of the dimer inter-
face (iG) was −7.1 kcal mol−1. The secondary structural elements
are summarised in Fig. 4a and the monomer structure is shown in
Fig. 4b. In the case of PSFMO, there was electron density for each
FMO using either NADH or NADPH as nicotinamide cofactor. Values for SMFMO,
NADPH
Conversion (%); absolute conﬁguration; e.e. (%)
SMFMO* CFMO PSFMO
. 2, (R)-, 57% e.e. 6, (S)-, 43% e.e. 28, (R)-, 24% e.e.
. 33, (R)-, 44% e.e. 32, (R)-, 32% e.e. 78, (R)-, 32% e.e.
. 1, n.d. 38, (R)-, 64% e.e. 73, (S)-, 4% e.e.
 <1, n.d. 11, (R)-, 3% e.e. No conversion
. 9, (R)-, 82% e.e. 47, (R)-, 77% e.e. 22, (R)-, 57% e.e.
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Fig. 3. (a) Primary structure of CFMO, with secondary structure assignment, created using DSSP [32,33] and represented using ALINE [34]. (b) Structure of dimer of CFMO, in
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mino acid in the monomer from residue Met1 to Pro354, which
llowed for the ﬁrst time the observation of the entire backbone
f the ﬂexible helix–loop–helix structure, represented by residues
07–234 in PSFMO, and incorporating helices 9 and 10, over FAD
hat had been missing from SMFMO  structures and only partially
resent in CFMO, although side-chain density for residues 222–227
as poor. Electron density was also present for residues Gly-2, Pro- and Ala 0 at the N-terminus, which represent the ﬁrst part of the
inker to the His-tag in the protein produced using the YSBLIC-3C
onstruct. The monomer of PSFMO superposed with the structure
f the SMFMO  with an r.m.s.d. of 0.90 A˚ over 327 C atoms. FAD was
ig. 4. (a) Primary structure of PSFMO, with secondary structure assignment, created usin
n  ribbon format. One FAD molecule per monomer is shown in cylinder format with c
elix–loop–helix structure over the active site, and for which electron density is continuoshown in cylinder format with carbon atoms in grey. Helix 8, which forms part of
 also highlighted. (For interpretation of the references to color in this ﬁgure legend,
again clearly visible in the omit map  after building and reﬁnement
of the protein atoms, and was also modelled and reﬁned success-
fully in the oxidised form, the density revealing no puckering of the
tricyclic ring system that might be indicative of the reduced ﬂavin.
3.5. The FAD binding region in CFMO and PSFMOIn both CFMO and PSFMO, the tricyclic isoalloxazine ring of FAD
was bound at the domain interface in a cavity beneath the ﬂexible
helix–loop–helix region of each enzyme (Fig. 5a and b). The oxygen
atoms of the pyrimidinedione ring form H-bonds with the backbone
g DSSP [32,33] and represented using ALINE [34]. (b) Structure of PSFMO monomer,
arbon atoms in grey. Helix 9, which with helix 10 forms part of the ﬂexible
us in the PSFMO structure, is also highlighted.
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Fig. 5. FAD environment within the active sites of (a) CFMO and (b) PSFMO. The peptide backbones are shown in with transparency levels of 30%. Amino acid side chains
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ADH. The poorer performance of NADPH-dependent biotransfor-
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ctive site during oxygenation, as has been observed for mFMO  [12].
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s  referred to the web version of this article.)MO. The FAD molecules are shown in cylinder format with carbon atoms in grey,
 was obtained through reﬁnement in the absence of FAD. The maps illustrate the
revealed that the phosphate binding sites for NADPH, including
the 2′ hydroxyl ribose phosphate that distinguishes NADPH from
NADH, were occupied by sulfate ions that had resulted from the
crystallisation conditions in lithium sulfate (Fig. 6a). This obser-
vation led to the hypothesis that substitution of arginine and
threonine residues in mFMO  for glutamine and histidine in SMFMO
were one of the factors that determined cofactor promiscuity in
the latter enzyme. Having acquired the structure of CFMO and
PSFMO, these were now superimposed with the structure of mFMO
in order to gain insight into the changes in the cofactor binding
loops that may  occur as a result of having threonine/serine and
glutamine/glutamate in these positions. In the case of CFMO the
side-chain oxygen atoms of Thr202 and Ser203 are both orientated
towards the putative phosphate binding site (Fig. 6b). The struc-
ture(s) of mFMO  had previously demonstrated that threonine is
able to make an effective contact with one of the phosphate oxygen
atoms of NADPH [12–14].
The nucleotide binding site of PSFMO featured a glycerol
molecule, from the cryoprotectant, occupying approximately
the same position as the adenine ring of NADPH in mFMO,  and
with the hydroxyl groups forming hydrogen bonds with the
side chain of Tyr140, the backbone NH of Gln194 and a water
molecule. Superimposition of the putative phosphate binding sites
of SMFMO  and PSFMO revealed that the backbone C atoms of
 and (c) PSFMO, each superimposed with the corresponding site in mFMO,  derived
 mFMO  are shown in grey in each case. Glc = glycerol in (c). Equivalent features for
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n PSFMO, Gln194 and Glu195 (Fig. 6c). However, the side chains
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utative phosphate binding site into the bulk solvent.
No data on the activity with mFMO  and NADH have been
eported, but other NADPH-speciﬁc FPMOs, such as NADPH-
ependent Baeyer–Villiger monooxygenases possess the Arg–Thr
ouple in common with mFMO  [16,17]. The studies with SMFMO
nd with CFMO and PSFMO reported herein suggest ﬁrst that a
ln–His couple favours NADH binding slightly, but that a Thr–Ser
ouple, as found in CFMO is superior for activity with both cofactors
verall. Counter-intuitively, the presence of a glutamate in the sec-
nd position of the couple, as found in PSFMO, does not prohibit
ADPH binding, but rather the Glu side chain is able to project away
rom the putative phosphate binding site. It is possible that the
resence of the glutamate side-chain allows selective recognition
f the NADH ribose oxygen atoms in the presence of that cofactor,
y rotating into the binding pocket, but is able to rotate away in the
resence of NADPH, thus allowing cofactor promiscuity in PSFMO.
ore detailed analysis awaits the acquisition of structures of these
nzymes in the presence of both NADPH and NADH however.
. Conclusion
CFMO and PSFMO provide new examples of enzymes within the
merging sub-family of cofactor-promiscuous ﬂavin-containing
onooxygenases, named ‘Type II FMOs’ by Fraaije and co-workers
7,11]. The study of this sub-class of FMOs is providing new infor-
ation on structure and evolutionary diversity within this family
f enzymes, and also suggesting new avenues for the engineering
f related enzymes for cofactor promiscuity with a view to greater
uitability for application in biocatalytic processes.
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